Czech National Bank raised its stake in Cencora, Inc. (NYSE:COR – Free Report) by 7.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,025 shares of the company’s stock after acquiring an additional 2,489 shares during the period. Czech National Bank’s holdings in Cencora were worth $8,543,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Concord Wealth Partners purchased a new position in Cencora during the 3rd quarter worth approximately $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora during the second quarter worth approximately $36,000. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the 3rd quarter valued at $41,000. Fairscale Capital LLC purchased a new stake in Cencora in the 2nd quarter valued at $54,000. Finally, Modus Advisors LLC acquired a new stake in Cencora during the 4th quarter worth $54,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have commented on the stock. Barclays lifted their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.
Cencora Stock Performance
NYSE:COR opened at $240.36 on Wednesday. The firm’s fifty day simple moving average is $237.95 and its 200-day simple moving average is $233.65. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The stock has a market cap of $46.46 billion, a PE ratio of 32.01, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27.
Cencora Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. Cencora’s dividend payout ratio (DPR) is 29.29%.
Insider Transactions at Cencora
In related news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 in the last quarter. 15.80% of the stock is currently owned by corporate insiders.
Cencora Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
- Five stocks we like better than Cencora
- EV Stocks and How to Profit from Them
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Business Services Stocks Investing
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.